↓ Skip to main content

Dove Medical Press

Imiglucerase in the treatment of Gaucher disease: a history and perspective

Overview of attention for article published in Drug Design, Development and Therapy, April 2012
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (81st percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

policy
1 policy source
twitter
1 X user
facebook
2 Facebook pages
wikipedia
10 Wikipedia pages

Citations

dimensions_citation
70 Dimensions

Readers on

mendeley
139 Mendeley
citeulike
1 CiteULike
Title
Imiglucerase in the treatment of Gaucher disease: a history and perspective
Published in
Drug Design, Development and Therapy, April 2012
DOI 10.2147/dddt.s14395
Pubmed ID
Authors

Patrick B Deegan, Timothy M Cox

Abstract

The scientific and therapeutic development of imiglucerase (Cerezyme(®)) by the Genzyme Corporation is a paradigm case for a critical examination of current trends in biotechnology. In this article the authors argue that contemporary interest in treatments for rare diseases by major pharmaceutical companies stems in large part from an exception among rarities: the astonishing commercial success of Cerezyme. The fortunes of the Genzyme Corporation, latterly acquired by global giant Sanofi SA, were founded on the evolution of a blockbuster therapy for a single but, as it turns out, propitious ultra-orphan disorder: Gaucher disease.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 139 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 <1%
Colombia 1 <1%
Germany 1 <1%
Austria 1 <1%
Unknown 135 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 26 19%
Student > Bachelor 25 18%
Student > Master 22 16%
Student > Ph. D. Student 14 10%
Student > Postgraduate 10 7%
Other 19 14%
Unknown 23 17%
Readers by discipline Count As %
Medicine and Dentistry 32 23%
Agricultural and Biological Sciences 20 14%
Biochemistry, Genetics and Molecular Biology 18 13%
Chemistry 14 10%
Pharmacology, Toxicology and Pharmaceutical Science 7 5%
Other 23 17%
Unknown 25 18%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 July 2022.
All research outputs
#4,888,682
of 25,584,565 outputs
Outputs from Drug Design, Development and Therapy
#305
of 2,254 outputs
Outputs of similar age
#30,559
of 173,277 outputs
Outputs of similar age from Drug Design, Development and Therapy
#1
of 5 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,254 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one has done well, scoring higher than 85% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 173,277 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them